本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：300149 证券简称：睿智医药 公告编号：2025-57 睿智医药科技股份有限公司 关于 2024 年度向特定对象发行股票申请 获得深圳证券交易所受理的公告 睿智医药科技股份有限公司（以下简称"公司"）近日收到深圳证券交易所（以 下简称"深交所"）出具的《关于受理睿智医药科技股份有限公司向特定对象发 行股票申请文件的通知》（深证上审〔2025〕161 号）。深交所依据相关规定对公 司报送的向特定对象发行股票的申请文件进行了核对，认为申请文件齐备，决定 予以受理。 公司本次向特定对象发行股票事项尚需深交所审核通过，并获得中国证券监 督管理委员会（以下简称"中国证监会"）同意注册后方可实施。最终能否通过 深交所审核并获得中国证监会同意注册的决定及时间尚存在不确定性。 公司将根据进展情况，严格按照上市公司向特定对象发行股票相关法律法规 的规定和要求及时履行信息披露义务，敬请投资者注意投资风险。 特此公告。 睿智医药科技股份有限公司 董事会 2025 年 8 月 27 日 ...

（广东省江门市江海区胜利南路 164 号） 证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司 （Chempartner Pharmatech Co.,Ltd.） 2024 年度向特定对象发行股票 募集说明书 （申报稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年八月 声 明 本公司及全体董事、高级管理人员承诺本募集说明书内容真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承担相应 的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责，投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引 ...

Core Insights - The company, Ruizhi Pharmaceutical, reported that as of August 8, 2025, the number of shareholders reached 52,505 [1] Summary by Category - **Company Information** - Ruizhi Pharmaceutical has a total of 52,505 shareholders as of the specified date [1]

Core Viewpoint - The company, Ruizhi Pharmaceutical, is a high-tech enterprise focused on pharmaceutical research and development (CRO/CDMO), providing one-stop services for global pharmaceutical companies, biotechnology firms, and research institutions from early discovery to commercial production [1] Company Overview - The main business of the company is contract research organization (CRO) services for new drug development, and it does not engage in the research and development of proprietary innovative drugs [1]

Group 1 - The restructuring protein sector is leading the market with an increase of 3.07% [1] - Key companies in this sector include Kaiyin Technology, which rose by 8.7%, and Saiseng Pharmaceutical, which increased by 7.3% [1] - Other notable performers are Maiwei Biotechnology with a rise of 6.86%, and Baipusais, Hite Biotechnology, and Ruizhi Pharmaceutical, all of which saw gains exceeding 4% [1]

Core Viewpoint - The company has successfully established an evaluation scheme for in vitro STAT6 inhibitors/degraders, aiding in the development of drugs targeting STAT6 for autoimmune diseases [1] Group 1: Company Developments - The in vitro pharmacological efficacy department of the company has developed a new evaluation scheme [1] - The focus of the evaluation scheme is on STAT6, a key member of the JAK-STAT signaling pathway [1] Group 2: Scientific Background - STAT6 acts as a transcriptional regulatory hub for the IL-4/IL-13 signaling pathway [1] - It plays a crucial role in immune processes such as Th2 cell differentiation and IgE class switching [1] - The protein is significant in regulating immune homeostasis and the pathological processes of autoimmune diseases [1]

Market Performance - On August 13, the medical services sector rose by 4.02%, led by Innovative Medical [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - The table lists various stocks in the medical services sector, with notable declines including *ST Bio down 4.95% and ST Zhongzhu down 2.66% [1] - Other stocks such as Lanwei Medical and Baicheng Pharmaceutical also experienced minor declines of 1.76% and 1.59% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.962 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.888 billion yuan [3] - Notable stocks with significant net inflows from institutional investors include Yaoming Kande with 1.13 billion yuan and Kanglong Huacheng with 248 million yuan [3] - Conversely, retail investors showed significant outflows from stocks like Yaoming Kande and Kanglong Huacheng, indicating a shift in investor sentiment [3]

Core Viewpoint - Recently, Ruizhi Pharmaceutical announced that its wholly-owned subsidiary has completed business registration and related procedures, obtaining a business license issued by the Market Supervision Administration of Yuexiu District, Guangzhou [2] Group 1 - The company has successfully registered its wholly-owned subsidiary [2] - The business license was issued by the Market Supervision Administration of Yuexiu District, Guangzhou [2]

证券代码：300149 证券简称：睿智医药 公告编号：2025-56 睿智医药科技股份有限公司 关于设立全资子公司进展暨完成工商登记的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 6 月 9 日召开了 第六届董事会第八次会议，审议通过了《关于设立健康产业全资子公司的议案》， 根据公司业务发展规划，同意公司使用自有资金 500 万元在广州设立全资子公司 广州睿莲安美健康科技有限公司（暂定名，具体以市场监督管理部门最终核准登 记名称为准）。具体内容详见公司于 2025 年 6 月 11 日在巨潮资讯网 （www.cninfo.com.cn）上披露的《关于投资设立全资子公司的公告》（公告编号： 2025-50）。 一、进展情况 近日，上述全资子公司已完成工商登记及相关手续，并取得了广州市越秀区 市场监督管理局颁发的《营业执照》，相关登记信息如下： 注册资本：人民币 500 万元 成立日期：2025 年 08 月 08 日 注册地址：广州市越秀区东风中路 268 号 2812 房（仅限办公） 经营范围：一 ...

Group 1 - The company, Ruizhi Pharmaceutical, focuses on pharmaceutical research and development as well as production services (CRO/CDMO) [1] - The company aims to provide one-stop services for global pharmaceutical enterprises, biotechnology companies, and research institutions, covering both chemical and biological drugs from early discovery to commercial production [1] - Currently, the company's main business does not involve medical devices [1]